查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595127

卵巢癌治療市場：按藥物類別、治療方式和藥物 - 2025-2030 年全球預測

Ovarian Cancer Drugs Market by Therapeutics Class (Angiogenesis Inhibitors, PARP Inhibitors, PD-L1 Inhibitors), Modality (Chemotherapy, Hormonal Therapy, Targeted Therapy), Drugs - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年卵巢癌治療市場價值為39.5億美元，預計到2024年將達到44.9億美元，複合年成長率為13.75%，到2030年將達到97.3億美元。

卵巢癌治療市場的範圍包括針對卵巢癌的藥物治療的開發、生產和分銷。這包括化療藥物、標靶治療和免疫治療。卵巢癌的高死亡率凸顯了對卵巢癌治療的需求，其主要原因往往是晚期診斷，因此為了提高存活率和患者預後，有效的藥物治療至關重要。治療的主要用途主要是腫瘤科醫師和醫療機構的治療系統，最終用途範圍包括醫院、專門的癌症治療中心和診所。

主要市場統計
基準年[2023] 39.5億美元
預測年份 [2024] 44.9億美元
預測年份 [2030] 97.3億美元
複合年成長率（%） 13.75%

市場成長受到個人化醫療進步、研發投資增加以及全球疾病意識增強等因素的顯著影響。包括標靶治療療法和聯合治療在內的創新治療方法的興起提供了巨大的成長潛力，新藥監管核准的增加也帶來了巨大的成長潛力。對微創治療方案和改善治療效果的需求不斷成長也為市場擴張創造了新的機會。利用這些機會的建議包括投資精準腫瘤學和透過策略聯盟加強患者的可及性。

然而，市場面臨高昂的藥物開發成本、嚴格的監管要求以及與現有療法相關的潛在副作用等限制。此外，卵巢癌的遺傳多樣性使得開發一種通用的治療方法變得困難，並且通常需要複雜的治療策略。

需要技術創新的領域包括開發用於早期檢測的生物標記、開發新的藥物傳輸系統以及利用人工智慧和基因組知識的針對患者的特異性治療方法。此外，這個市場的性質既是競爭性的，也是協作性的，製藥公司、生技公司和研究機構形成夥伴關係。專注於突破性治療方法和適應性臨床試驗設計的公司將在這個不斷發展的市場格局中處於領先地位。鑑於這些動態，相關人員應優先考慮以患者為中心的設計和數位整合醫療保健解決方案，以促進長期創新和成長。

市場動態：揭示快速發展的卵巢癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變卵巢癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球卵巢癌發生率上升
    • 世界女性老化人口成長
    • 新藥採用和強大的開發平臺
  • 市場限制因素
    • 抗癌藥物對人體的不良影響
  • 市場機會
    • 政府增加對新興國家醫療保健產業的資助
    • 新興經濟體卵巢癌藥物的開發
  • 市場挑戰
    • 卵巢癌治療費用高

波特五力：駕馭卵巢癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解卵巢癌藥物市場的外部影響

外部宏觀環境因素在塑造卵巢癌治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解卵巢癌治療藥物市場的競爭狀況

卵巢癌治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣卵巢癌治療市場供應商的績效評估

FPNV定位矩陣是評估卵巢癌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃卵巢癌治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對卵巢癌治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球卵巢癌發生率增加
      • 世界各地老年婦女的數量正在增加。
      • 新藥推出和強大的開發平臺
    • 抑制因素
      • 抗癌藥物對人體的不良影響
    • 機會
      • 政府增加對新興國家醫療保健產業的資助
      • 新興經濟體卵巢癌藥物的趨勢
    • 任務
      • 治療卵巢癌的費用很高
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的卵巢癌治療藥物市場

  • 血管新生抑制劑
  • PARP抑制劑
  • PD-L1抑制劑

第7章卵巢癌治療藥物市場：按方式

  • 化療
  • 荷爾蒙療法
  • 標靶治療

第8章卵巢癌治療藥物市場（按藥物）

  • Avastin
  • Carboplatin
  • Doxil
  • 林帕爾札
  • Yondelis

第9章北美和南美卵巢癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區卵巢癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲卵巢癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Allergan PLC
  • AstraZeneca PLC
  • Boehringer Ingelheim
  • Cipla Ltd.
  • Clovis Oncology
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi India Pvt. Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals Pvt. Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Syndax Pharmaceuticals, Inc.
Product Code: MRR-434CCDA052A2

The Ovarian Cancer Drugs Market was valued at USD 3.95 billion in 2023, expected to reach USD 4.49 billion in 2024, and is projected to grow at a CAGR of 13.75%, to USD 9.73 billion by 2030.

The scope of the ovarian cancer drugs market encompasses the development, production, and distribution of pharmacological treatments specifically designed to target ovarian cancer. This includes chemotherapeutic agents, targeted therapies, and immunotherapies. The necessity of ovarian cancer drugs is underscored by the high mortality rates associated with ovarian cancer, largely due to the often late-stage diagnosis, making effective drug therapies vital for improving survival rates and patient outcomes. Applications primarily include usage by oncologists and healthcare facilities for treatment regimes, with end-use spanning hospitals, specialty cancer treatment centers, and clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 3.95 billion
Estimated Year [2024] USD 4.49 billion
Forecast Year [2030] USD 9.73 billion
CAGR (%) 13.75%

Market growth is significantly influenced by factors such as advancements in personalized medicine, increased R&D investments, and expanding global awareness of the disease. The rise of innovative therapies, including targeted and combination therapies, offers substantial growth potential, as does the increasing regulatory approval of novel drugs. The growing demand for minimally invasive treatment options and improved therapeutic outcomes also creates new opportunities for market expansion. Recommendations to capitalize on these opportunities include investing in precision oncology and enhancing patient access through strategic partnerships.

However, the market faces limitations such as high drug development costs, stringent regulatory requirements, and potential side effects associated with existing therapies. Additionally, the genetic diversity of ovarian cancer makes it challenging to develop a one-size-fits-all treatment, often requiring complex treatment strategies.

Areas ripe for innovation include the development of biomarkers for early detection, novel drug delivery systems, and patient-specific treatment options leveraging artificial intelligence and genomic insights. Furthermore, the nature of the market is competitive yet collaborative, involving partnerships between pharmaceutical firms, biotechnology companies, and research institutions. Companies that focus on breakthrough therapies and adaptive clinical trial designs are well-positioned to lead in this evolving market landscape. Given these dynamics, stakeholders should prioritize patient-centric design and digitally integrated healthcare solutions to foster long-term innovation and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ovarian Cancer Drugs Market

The Ovarian Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of ovarian cancer around the globe
    • Increasing geriatric population of women around the world
    • Adoption of novel drugs and strong developmental pipeline
  • Market Restraints
    • Adverse impact of cancer drugs on the human body
  • Market Opportunities
    • Rising funding in the healthcare industry by the government in developing countries
    • Developments in ovarian cancer drugs in emerging economies
  • Market Challenges
    • Cost associated with the treatment of ovarian cancer is high

Porter's Five Forces: A Strategic Tool for Navigating the Ovarian Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ovarian Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ovarian Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ovarian Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ovarian Cancer Drugs Market

A detailed market share analysis in the Ovarian Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ovarian Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ovarian Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ovarian Cancer Drugs Market

A strategic analysis of the Ovarian Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim, Cipla Ltd., Clovis Oncology, F. Hoffmann-La Roche AG, Fresenius Kabi India Pvt. Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Mylan Pharmaceuticals Pvt. Ltd., Pfizer, Inc., Sanofi S.A., and Syndax Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics Class, market is studied across Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors.
  • Based on Modality, market is studied across Chemotherapy, Hormonal Therapy, and Targeted Therapy.
  • Based on Drugs, market is studied across Avastin, Carboplatin, Doxil, Lynparza, and Yondelis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of ovarian cancer around the globe
      • 5.1.1.2. Increasing geriatric population of women around the world
      • 5.1.1.3. Adoption of novel drugs and strong developmental pipeline
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse impact of cancer drugs on the human body
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
      • 5.1.3.2. Developments in ovarian cancer drugs in emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Cost associated with the treatment of ovarian cancer is high
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ovarian Cancer Drugs Market, by Therapeutics Class

  • 6.1. Introduction
  • 6.2. Angiogenesis Inhibitors
  • 6.3. PARP Inhibitors
  • 6.4. PD-L1 Inhibitors

7. Ovarian Cancer Drugs Market, by Modality

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Targeted Therapy

8. Ovarian Cancer Drugs Market, by Drugs

  • 8.1. Introduction
  • 8.2. Avastin
  • 8.3. Carboplatin
  • 8.4. Doxil
  • 8.5. Lynparza
  • 8.6. Yondelis

9. Americas Ovarian Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ovarian Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Ltd.
  • 3. Allergan PLC
  • 4. AstraZeneca PLC
  • 5. Boehringer Ingelheim
  • 6. Cipla Ltd.
  • 7. Clovis Oncology
  • 8. F. Hoffmann-La Roche AG
  • 9. Fresenius Kabi India Pvt. Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Merck & Co., Inc.
  • 12. Mylan Pharmaceuticals Pvt. Ltd.
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Syndax Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. OVARIAN CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OVARIAN CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVARIAN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVARIAN CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023